Last reviewed · How we verify
DT-101
DT-101 is a small molecule that targets the CDK4/6 pathway.
DT-101 is a small molecule that targets the CDK4/6 pathway. Used for Breast cancer, estrogen receptor-positive, HER2-negative, Breast cancer, estrogen receptor-positive, HER2-positive.
At a glance
| Generic name | DT-101 |
|---|---|
| Sponsor | Draig Therapeutics Ltd |
| Drug class | CDK4/6 inhibitor |
| Target | CDK4/6 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
DT-101 works by inhibiting the CDK4/6 enzymes, which are involved in cell cycle progression. This leads to a decrease in cell proliferation and an increase in cell death, making it a potential treatment for various cancers.
Approved indications
- Breast cancer, estrogen receptor-positive, HER2-negative
- Breast cancer, estrogen receptor-positive, HER2-positive
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Vomiting
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DT-101 CI brief — competitive landscape report
- DT-101 updates RSS · CI watch RSS
- Draig Therapeutics Ltd portfolio CI